Silver Book Fact

Potential cost effectiveness of shingles vaccines

The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal perspective.

Pellesier, James M., Marc Brisson, and Myron J. Levin. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine. 2007; 25(49): 8326-37. http://www.ncbi.nlm.nih.gov/pubmed/17980938

Reference

Title
Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
Vaccine
Publication Date
2007
Authors
Pellesier, James M., Marc Brisson, and Myron J. Levin
Volume & Issue
Volume 25, Issue 49
Pages
8326-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Over 8 years infection control practices saved ~27,000 lives and $1.8 billion
    Infection control practices saved an estimated 27,000 lives and $1.8 billion in medical costs between 2001 and 2009.  
  • Flu vaccine use reduces disease burden
    Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also…  
  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
  • ~One-third of shingles death preventable with vaccine
    Approximately one-third of shingles deaths may be preventable through vaccination.